Targeting PP2A to overcome enzalutamide resistance in AR plus breast tumors

被引：1
|
作者：
Cristobal, Ion [1 ]
Torrejon, Blanca [1 ]
Pedregal, Manuel [1 ]
Rojo, Federico [2 ]
Garcia-Foncillas, Jesus [1 ]
机构：
[1] Univ Hosp Fdn Jimenez Diaz, IIS Fdn Jimenez Diaz UAM, Translat Oncol Div, Oncohlth Inst, Madrid, Spain
[2] Univ Hosp Fdn Jimenez Diaz, IIS Fdn Jimenez Diaz UAM, Pathol Dept, Madrid, Spain
来源：
ENDOCRINE-RELATED CANCER | 2017年 / 24卷 / 01期
关键词：
ANDROGEN RECEPTOR; PROSTATE-CANCER; INHIBITOR; EXPRESSION; CELLS; AXIS;
D O I：
10.1530/ERC-16-0444
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：L5 / L6
页数：2
相关论文
共 50 条
  • [41] Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem
    Wahdan-Alaswad, Reema
    Liu, Bolin
    Thor, Ann D.
    CANCER DRUG RESISTANCE, 2020, 3 (02) : 179 - 198
  • [42] MicroRNA-383-5p inhibits the proliferation and promotes the apoptosis of gastric cancer cells by targeting cancerous inhibitor of PP2A
    Li, Xinxin
    Yuan, Jinpeng
    Cao, Qiangjian
    Xie, Aosi
    Chen, Juntian
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 46 (01) : 397 - 405
  • [43] Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer
    Ho, Chien-Yi
    Wei, Cheng-Yen
    Zhao, Ruo-Wen
    Ye, Yi-Lun
    Huang, Hui-Chi
    Lee, Jen-Chih
    Cheng, Fang-Ju
    Huang, Wei-Chien
    ENVIRONMENTAL TOXICOLOGY, 2024, 39 (06) : 3389 - 3399
  • [44] Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
    Rodriguez, Maria Jimena
    Perrone, Maria Cecilia
    Riggio, Marina
    Palafox, Marta
    Salinas, Valeria
    Elia, Andres
    Salgueiro, Natali Daiana
    Werbach, Andrea Eugenia
    Marks, Maria Paula
    Kauffman, Marcelo A.
    Vellon, Luciano
    Serra, Violeta
    Novaro, Virginia
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [45] Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
    Wang, Zhen-hao
    Zheng, Zhuo-qun
    Jia, Shi-cheng
    Liu, Shu-ni
    Xiao, Xiao-fen
    Chen, Guan-yuan
    Liang, Wei-quan
    Lu, Xiao-feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER plus breast cancer
    Ward, Aoife
    Shukla, Kirti
    Balwierz, Aleksandra
    Soons, Zita
    Koenig, Rainer
    Sahin, Oezguer
    Wiemann, Stefan
    JOURNAL OF PATHOLOGY, 2014, 233 (04): : 368 - 379
  • [47] NAR Breakthrough Article Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
    Chan, Siu Chiu
    Selth, Luke A.
    Li, Yingming
    Nyquist, Michael D.
    Miao, Lu
    Bradner, James E.
    Raj, Ganesh V.
    Tilley, Wayne D.
    Dehm, Scott M.
    NUCLEIC ACIDS RESEARCH, 2015, 43 (12) : 5880 - 5897
  • [48] Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells
    Ozel, Buket
    Kipcak, Sezgi
    Avci, Cigir Biray
    Gunduz, Cumhur
    Saydam, Guray
    Aktan, Cagdas
    Gunel, Nur Selvi
    MEDICAL ONCOLOGY, 2022, 39 (04)
  • [49] A genetic variant in a PP2A regulatory subunit encoded by the PPP2R2B gene associates with altered breast cancer risk and recurrence
    Vazquez, Alexei
    Kulkarni, Diptee
    Grochola, Lukasz F.
    Bond, Gareth L.
    Barnard, Nicola
    Toppmeyer, Deborah
    Levine, Arnold J.
    Hirshfield, Kim M.
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (10) : 2335 - 2343
  • [50] Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER plus breast cancer
    Attia, Yasmin M.
    Salama, Salama A.
    Shouman, Samia A.
    Ivan, Cristina
    Elsayed, Abdelrahman M.
    Amero, Paola
    Rodriguez-Aguayo, Cristian
    Lopez-Berestein, Gabriel
    PHARMACOLOGICAL REPORTS, 2022, 74 (02) : 366 - 378
12345